Bristol-Myers Squibb Reacquires Rights to ASLAN002
BMS will reacquire the rights to ASLAN002 (BMS777607) from ASLAN Pharmaceuticals in China, Australia, Korea, Taiwan, and other Asian territories.
On August 10, 2016, ASLAN Pharmaceuticals announced that Bristol-Myers Squibb (BMS) is reacquiring the rights to ASLAN002 in China, Australia, Korea, Taiwan, and other Asian territories. ASLAN in-licensed ASLAN002, a small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint, in these markets from BMS in November 2011.
ASLAN will receive an upfront payment of $10 million. The company is also eligible to receive development and regulatory milestones in excess of $50 million and future royalty payments on worldwide sales. BMS will resume responsibility for all development and commercialization activities and expenses.
According to ASLAN, a Phase I study of ASLAN002 showed it to be safe and well tolerated. Data from the study also showed that “inhibition of RON resulted in potent inhibition of plasma biomarkers of RON activity,” the company said in a press release.
Source: ASLAN Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
